Compassionate Use of Certolizumab Pegol in Patients with Crohn's Disease Who Have Failed Previous TNF Inhibitor Therapies

被引：0
|
作者：
Vermeire, Severine [1 ]
Howaldt, Stefanie
Hommes, Daan [2 ]
Bressler, Brian [3 ]
Colombel, Jean-Frederic [4 ]
Mitchev, Krassimir [5 ]
Rutgeerts, Paul [1 ]
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Leiden Univ, Leiden, Netherlands
[3] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada
[4] Hop Claude Huriez, Lille, France
[5] UCB, Briane Lalleud, Belgium
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2010年 / 105卷
关键词：
D O I：
10.14309/00000434-201010001-01149
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1149
引用
收藏
页码：S416 / S416
页数：1
相关论文
共 50 条
  • [21] Certolizumab pegol - A pegylated anti-TNF-alpha antibody fragment for the treatment of Crohn's disease
    Schlesselman, Lauren S.
    FORMULARY, 2008, 43 (01) : 22 - 28
  • [22] Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
    Sandborn, William J.
    Abreu, Maria T.
    D'Haens, Geert
    Colombel, Jean-Frederic
    Vermeire, Severine
    Mitchev, Krassimir
    Jamoul, Corinne
    Fedorak, Richard N.
    Spehlmann, Martina E.
    Wolf, Douglas C.
    Lee, Scott
    Rutgeerts, Paul
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (08) : 688 - 695
  • [23] Mucosal Healing in Patients Receiving Certolizumab Pegol for Crohn's Disease (CHARTER Study)
    Randall, Charles
    Herrera, Christian
    Taboada, Carlo
    Fincke, Christopher
    Havranek, Russell
    Zurita, Franz
    Stump, David
    Gossen, Gary
    Vidaurri, Daniela
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S436 - S437
  • [24] CIMZIA (Certolizumab Pegol) is effective in the treatment of Crohn's Disease patients with open fistulas
    Schreiber, S.
    Lawranc, I
    Thomsen, O.
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S1 - S1
  • [25] Rapid response to adalimumab in Crohn's disease patients who have failed infliximah
    D'haens, Geert R.
    Enns, Robert A.
    Van assche, Gen
    Kent, Jeffrey D.
    Li, Ju
    Pollack, Paul F.
    Rubin, David T.
    GASTROENTEROLOGY, 2007, 132 (04) : A502 - A502
  • [26] Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use
    Danese, Silvio
    Mocciaro, Filippo
    Guidi, Luisa
    Scribano, Maria Lia
    Comberlato, Michele
    Annese, Vito
    Colombo, Elisabetta
    Stefanelli, Tommaso
    Marzo, Manuela
    Vangeli, Marcello
    Pulitano, Raffaella
    Manca, Aldo
    Armuzzi, Alessandro
    Malesci, Alberto
    Prantera, Cosimo
    Cottone, Mario
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (08) : 1168 - 1170
  • [27] Cost-effectiveness of natalizumab in Crohn's disease patients who have failed anti-TNF alpha therapy
    Sands, Bruce E.
    Wolf, Douglas C.
    Panjabi, Sumeet
    Niecko, Timothy
    Hass, Steven
    Lacey, Loretto
    Spencer, Mike
    GASTROENTEROLOGY, 2008, 134 (04) : A638 - A638
  • [28] Cost-effectiveness of natalizumab in Crohn's disease patients who have failed anti-TNF alpha therapy
    Panjabi, S.
    Niecko, T.
    Hass, S. L.
    Lacey, L.
    Spencer, M. D.
    VALUE IN HEALTH, 2008, 11 (03) : A85 - A85
  • [29] Crohn's disease - infliximab, adalimumab and certolizumab-pegol: clinical value of anti-TNF-α treatment
    Schreiber, S.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2007, 132 (34-35) : 1770 - 1774
  • [30] Clinical Correlates and Pharmacokinetic Parameters of Certolizumab Pegol Predicted by Modeling in Patients With Crohn's Disease
    Wade, Janet
    Oliver, Ruth
    Parker, Gerry
    Kosutic, Gordana
    Feagan, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S510 - S510
12345